Paulo Lee Ho holds a Bachelor’s degree in Biological Sciences from the University of São Paulo (1984), a PhD in Biological Sciences (Biochemistry) from the University of São Paulo (1989) and a Post-Doctorate degree from Columbia University (USA, 1993). He is Scientific Researcher VI at Instituto Butantan and former Director of the Biotechnology Center (2002-2010), former Director of the Division of Technological Development and Production (2012-2016) of Instituto Butantan. During his tenure as Director of this Division, he was responsible for starting the production of the trivalent influenza vaccine (2013) and the production of equine immunoglobulins (“sera”) for antivenom, antitoxin and antiviral therapies (2014) in industrial units with Good Manufacturing Practices certifications by ANVISA. Actively participated in the Tech-Transfer agreements of the quadrivalent HPV vaccine MSD to the Butantan Institute, the Tech-Transfer of the Dengue vaccine from Butantan to MSD, the acellular pertussis vaccine GSK to the Butantan Institute and also the initiatives to prepare for a potential influenza pandemic in the country with support from WHO and BARDA (USA). He was a member of the National Technical Committee for Biosafety (CTNBio, 2012-2016) and is currently Academic Editor of PLoS One (2008 to date). He has more than 160 articles published in peer-reviewed journals, H index = 41, patents in Brazil and abroad. He has received honors such as the Medal of Science and Technology from the São Paulo State Government for the sequencing of the genome of the phytobacterium Xylella fastidiosa (2000), Medal of Excellence in Pharmaceutical Development by the Academy of Pharmaceutical Sciences (2016), Albas Lavras Medal from the Association of Research Scientists (APqC) of the State of São Paulo (2016) and several Awards, such as the Biotech-Space Full Researcher Award 2016 and the Butantan Foundation Award 2017, among others. He has technical and scientific contributions in the areas of vaccine development, biotechnology, genomics, toxinology and cell biology. He is currently a CNPq 1C fellow.